Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic obstructive pulmonary disease (COPD) is a disease associated with significant morbidity and mortality. The current GOLD guidelines recognize that the impact of COPD on an individual patient depends not just on the degree of airflow limitation, but also on the severity of symptoms (especially breathlessness and decreased exercise capacity), systemic effects, and any comorbidities the patient may have. Furthermore, COPD should be managed as a systemic disorder, with careful attention paid to comorbidities and their effect on the patient's quality of life. The main concomitant conditions associated with COPD are skeletal muscle weakness, osteoporosis, heart failure, cardiac arrhythmias, ischemic heart disease, stroke, depression, cancer etc. Recently, several investigators proposed that potentially a common mechanism by which major risk factors such as smoking, hyperlipidemia, obesity lead to chronic disease is systemic inflammation. Systemic inflammation may explain the development of chronic diseases such as COPD and its association with systemic and complex abnormalities affecting other organs. It has been suggested that persistent pulmonary inflammation promotes the release of pro-inflammatory chemokines and cytokines into the circulations. These mediators then stimulate various end-organs such as liver, adipose tissue, bone marrow that will release excessive amounts of acute phase proteins, inflammatory cells and secondary cytokines into the circulation and the result is a state of persistent low-grade systemic inflammation. The main controversia that exist today relates to the source in the respiratory system of inflammation. There is increased evidence that the functional impairment of airway-bronchial constriction that results in increased workload, hyperinflation and impaired respiratory muscle function is the main sources of inflammation. Recent reports characterize the upregulation of pro-inflammatory cytokines in the intercostals and other respiratory muscles. In theory, anti-inflammatory treatment should contribute to the reduction of exacerbations. Clinical studies that involve the use of long-acting bronchodilators, with or without inhaled corticosteroids; or surgical interventions such as volume reduction surgery have been associated with significant reduction in COPD exacerbation. Therefore, COPD is a disease associated with multiple co-morbid conditions, but the physiological consequences of airway obstruction, mainly hyperinflation may be the main precipitating factor of the systemic inflammatory response seen in these patients.

Original languageEnglish (US)
Title of host publicationCOPD Is/Is Not a Systemic Disease?
PublisherNova Science Publishers, Inc.
Pages115-124
Number of pages10
ISBN (Print)9781608760510
StatePublished - 2010

Fingerprint

Chronic Obstructive Pulmonary Disease
Disease Progression
Biomarkers
Inflammation
Respiratory Muscles
Cytokines
Comorbidity
Chronic Disease
Precipitating Factors
Bronchoconstriction
Acute-Phase Proteins
Bronchodilator Agents
Muscle Weakness
Airway Obstruction
Hyperlipidemias
Workload
Chemokines
Respiratory System
Dyspnea
Osteoporosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Anzueto, A. R. (2010). Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No. In COPD Is/Is Not a Systemic Disease? (pp. 115-124). Nova Science Publishers, Inc..

Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No. / Anzueto, Antonio R.

COPD Is/Is Not a Systemic Disease?. Nova Science Publishers, Inc., 2010. p. 115-124.

Research output: Chapter in Book/Report/Conference proceedingChapter

Anzueto, AR 2010, Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No. in COPD Is/Is Not a Systemic Disease?. Nova Science Publishers, Inc., pp. 115-124.
Anzueto AR. Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No. In COPD Is/Is Not a Systemic Disease?. Nova Science Publishers, Inc. 2010. p. 115-124
Anzueto, Antonio R. / Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No. COPD Is/Is Not a Systemic Disease?. Nova Science Publishers, Inc., 2010. pp. 115-124
@inbook{013518ff3dd941b48d8cb7d9e321d78c,
title = "Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No",
abstract = "Chronic obstructive pulmonary disease (COPD) is a disease associated with significant morbidity and mortality. The current GOLD guidelines recognize that the impact of COPD on an individual patient depends not just on the degree of airflow limitation, but also on the severity of symptoms (especially breathlessness and decreased exercise capacity), systemic effects, and any comorbidities the patient may have. Furthermore, COPD should be managed as a systemic disorder, with careful attention paid to comorbidities and their effect on the patient's quality of life. The main concomitant conditions associated with COPD are skeletal muscle weakness, osteoporosis, heart failure, cardiac arrhythmias, ischemic heart disease, stroke, depression, cancer etc. Recently, several investigators proposed that potentially a common mechanism by which major risk factors such as smoking, hyperlipidemia, obesity lead to chronic disease is systemic inflammation. Systemic inflammation may explain the development of chronic diseases such as COPD and its association with systemic and complex abnormalities affecting other organs. It has been suggested that persistent pulmonary inflammation promotes the release of pro-inflammatory chemokines and cytokines into the circulations. These mediators then stimulate various end-organs such as liver, adipose tissue, bone marrow that will release excessive amounts of acute phase proteins, inflammatory cells and secondary cytokines into the circulation and the result is a state of persistent low-grade systemic inflammation. The main controversia that exist today relates to the source in the respiratory system of inflammation. There is increased evidence that the functional impairment of airway-bronchial constriction that results in increased workload, hyperinflation and impaired respiratory muscle function is the main sources of inflammation. Recent reports characterize the upregulation of pro-inflammatory cytokines in the intercostals and other respiratory muscles. In theory, anti-inflammatory treatment should contribute to the reduction of exacerbations. Clinical studies that involve the use of long-acting bronchodilators, with or without inhaled corticosteroids; or surgical interventions such as volume reduction surgery have been associated with significant reduction in COPD exacerbation. Therefore, COPD is a disease associated with multiple co-morbid conditions, but the physiological consequences of airway obstruction, mainly hyperinflation may be the main precipitating factor of the systemic inflammatory response seen in these patients.",
author = "Anzueto, {Antonio R}",
year = "2010",
language = "English (US)",
isbn = "9781608760510",
pages = "115--124",
booktitle = "COPD Is/Is Not a Systemic Disease?",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Is there evidence from biomarkers of systemic involvement in COPD exacerbations? No

AU - Anzueto, Antonio R

PY - 2010

Y1 - 2010

N2 - Chronic obstructive pulmonary disease (COPD) is a disease associated with significant morbidity and mortality. The current GOLD guidelines recognize that the impact of COPD on an individual patient depends not just on the degree of airflow limitation, but also on the severity of symptoms (especially breathlessness and decreased exercise capacity), systemic effects, and any comorbidities the patient may have. Furthermore, COPD should be managed as a systemic disorder, with careful attention paid to comorbidities and their effect on the patient's quality of life. The main concomitant conditions associated with COPD are skeletal muscle weakness, osteoporosis, heart failure, cardiac arrhythmias, ischemic heart disease, stroke, depression, cancer etc. Recently, several investigators proposed that potentially a common mechanism by which major risk factors such as smoking, hyperlipidemia, obesity lead to chronic disease is systemic inflammation. Systemic inflammation may explain the development of chronic diseases such as COPD and its association with systemic and complex abnormalities affecting other organs. It has been suggested that persistent pulmonary inflammation promotes the release of pro-inflammatory chemokines and cytokines into the circulations. These mediators then stimulate various end-organs such as liver, adipose tissue, bone marrow that will release excessive amounts of acute phase proteins, inflammatory cells and secondary cytokines into the circulation and the result is a state of persistent low-grade systemic inflammation. The main controversia that exist today relates to the source in the respiratory system of inflammation. There is increased evidence that the functional impairment of airway-bronchial constriction that results in increased workload, hyperinflation and impaired respiratory muscle function is the main sources of inflammation. Recent reports characterize the upregulation of pro-inflammatory cytokines in the intercostals and other respiratory muscles. In theory, anti-inflammatory treatment should contribute to the reduction of exacerbations. Clinical studies that involve the use of long-acting bronchodilators, with or without inhaled corticosteroids; or surgical interventions such as volume reduction surgery have been associated with significant reduction in COPD exacerbation. Therefore, COPD is a disease associated with multiple co-morbid conditions, but the physiological consequences of airway obstruction, mainly hyperinflation may be the main precipitating factor of the systemic inflammatory response seen in these patients.

AB - Chronic obstructive pulmonary disease (COPD) is a disease associated with significant morbidity and mortality. The current GOLD guidelines recognize that the impact of COPD on an individual patient depends not just on the degree of airflow limitation, but also on the severity of symptoms (especially breathlessness and decreased exercise capacity), systemic effects, and any comorbidities the patient may have. Furthermore, COPD should be managed as a systemic disorder, with careful attention paid to comorbidities and their effect on the patient's quality of life. The main concomitant conditions associated with COPD are skeletal muscle weakness, osteoporosis, heart failure, cardiac arrhythmias, ischemic heart disease, stroke, depression, cancer etc. Recently, several investigators proposed that potentially a common mechanism by which major risk factors such as smoking, hyperlipidemia, obesity lead to chronic disease is systemic inflammation. Systemic inflammation may explain the development of chronic diseases such as COPD and its association with systemic and complex abnormalities affecting other organs. It has been suggested that persistent pulmonary inflammation promotes the release of pro-inflammatory chemokines and cytokines into the circulations. These mediators then stimulate various end-organs such as liver, adipose tissue, bone marrow that will release excessive amounts of acute phase proteins, inflammatory cells and secondary cytokines into the circulation and the result is a state of persistent low-grade systemic inflammation. The main controversia that exist today relates to the source in the respiratory system of inflammation. There is increased evidence that the functional impairment of airway-bronchial constriction that results in increased workload, hyperinflation and impaired respiratory muscle function is the main sources of inflammation. Recent reports characterize the upregulation of pro-inflammatory cytokines in the intercostals and other respiratory muscles. In theory, anti-inflammatory treatment should contribute to the reduction of exacerbations. Clinical studies that involve the use of long-acting bronchodilators, with or without inhaled corticosteroids; or surgical interventions such as volume reduction surgery have been associated with significant reduction in COPD exacerbation. Therefore, COPD is a disease associated with multiple co-morbid conditions, but the physiological consequences of airway obstruction, mainly hyperinflation may be the main precipitating factor of the systemic inflammatory response seen in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84892030766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892030766&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892030766

SN - 9781608760510

SP - 115

EP - 124

BT - COPD Is/Is Not a Systemic Disease?

PB - Nova Science Publishers, Inc.

ER -